Dose Escalation Study of Immunomodulatory Nanoparticles
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
PRECIOUS-01 is an immunomodulating agent composed of the invariant natural killer T cell
(iNKT) activator threitolceramide-6 (ThrCer6, IMM60) and the New York Esophageal Squamous
Cell Carcinoma-1 (NY-ESO-1) cancer-testis antigen peptides encapsulated in a
poly(lactic-co-glycolic acid) (PLGA) nanoparticle.
PRECIOUS-01 is being developed for the treatment of patients with NY-ESO-1-positive cancers.